IQV250516C95000
- 0.00
- 0.000.00%
IQVIA Holdings Newsroom
Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $211
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $161 to $209
Express News | IQVIA Holdings Inc : Morgan Stanley Cuts Target Price to $185.00 From $250.00
When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
New Analyst Forecast: $IQV Given $165.0 Price Target
IQVIA CFO Ron Bruehlman to Speak at the Bank of America Annual Health Care Conference on May 13
IQVIA Holdings Is Maintained at Neutral by Baird
IQVIA Holdings Is Maintained at Buy by UBS
IQVIA Holdings Price Target Cut to $185.00/Share From $255.00 by UBS
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $165 to $168
Leerink Partners Adjusts Price Target on IQVIA Holdings to $210 From $245, Maintains Outperform Rating
Express News | Barclays Maintains Equal-Weight on IQVIA Hldgs, Lowers Price Target to $165
IQVIA Hldgs Analyst Ratings
Express News | IQVIA Holdings Inc : Deutsche Bank Cuts Target Price to $200 From $260
Evercore ISI Sticks to Its Buy Rating for IQVIA Holdings (IQV)
Express News | IQVIA Holdings Inc : Baird Cuts Target Price to $161 From $195
Resilience and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Industry Challenges
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
IQVIA Holdings' Earnings Call: Mixed Sentiment Amid Growth
IQVIA Holdings | 10-Q: Q1 2025 Earnings Report